Importance of Bcl-2 with respect to hematologic malignancies is indirectly documented by the fact that targeting of Bcl-2, by ABT-199, but not Bcl-XL is associated with promising clinical results in CLL and AML [14]. Here, BCL2 is linked to acute myeloid leukemia.